Youth Mayo Clinic Anxiety Coach Randomized Controlled Trial
Study Details
Study Description
Brief Summary
This research study aims to test the feasibility and effectiveness of using the Mayo Clinic Anxiety Coach smartphone app as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have limited access to mental health treatment in the traditional clinical setting.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
60 therapists in underserved areas will treat children with anxiety disorders in one of three conditions (treatment as usual, Anxiety Coach with face-to-face therapy, or Anxiety Coach with minimal direct contact) to determine the feasibility of using of Anxiety Coach to increase the frequency of exposure and improve outcomes with varying degrees of face-to-face contact (N = 60 patients).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Face-to-Face w/ Anxiety Coach (FTF-AC) In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal. |
Device: Mayo Clinic Anxiety Coach
Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
|
Experimental: Treatment as Usual (TAU) In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment. |
Other: Treatment as Usual
In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
|
Outcome Measures
Primary Outcome Measures
- Mean change from Baseline in Pediatric Anxiety Rating Scale (PARS) at Treatment Completion [Within 5 working days of Treatment Completion]
The Pediatric Anxiety Rating Scale (PARS) is an interview-based tool used to assess for the presence and severity of anxiety symptoms in children and adolescents utilizing parental and youth input to guide clinician ratings.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 7 to 17
-
Primary diagnosis of:
-
social phobia,
-
separation anxiety disorder,
-
panic disorder with and without agoraphobia,
-
specific phobia, or
-
obsessive compulsive disorder
-
A parent or other primary care giver available to participate with the child in all assessment and treatment activities
-
Estimated average intelligence
-
English speaking
Exclusion Criteria:
-
History of and/or current diagnosis of:
-
psychosis,
-
autism,
-
bipolar disorder,
-
mental retardation,
-
oppositional defiant disorder,
-
PTSD,
-
selective mutism, or
-
major depressive disorder
-
Current suicidality or recent suicidal behavior
-
Parent to be involved in study who is unable to adequately participate due to intellectual or psychiatric difficulties
-
Starting or changing the dosage of a psychiatric medication in the last two months
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Stephen Whiteside
- National Institute of Mental Health (NIMH)
Investigators
- Principal Investigator: Stephen Whiteside, Ph.D., L.P., Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 13-000288 - RCT
- R34MH100468